Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Neveu

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|June 22, 2005
Tintin in CMAJDavid Neveu
Vaccine|June 23, 2020
Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: A Phase III randomized studyMandeep S Dhingra, James Peterson, James Hedrick, et al.
Infectious Diseases and Therapy|January 13, 2021
Post-Marketing Surveillance Observational Study of Quadrivalent Meningococcal Diphtheria Toxoid Conjugate Vaccine (MenACWY-DT, MCV4/Menactra<sup>®</sup>) in the Republic of Korea, 2014-2019Hee Soo Kim, Solene Engel, David Neveu, et al.
Vaccine|February 25, 2025
Corrigendum to "Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: A Phase III randomized study" [Vaccine (38) (2020) 5194-5201]Mandeep S Dhingra, James Peterson, James Hedrick, et al.
Vaccine|May 11, 2020
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in ≥56-year-olds: A Phase III randomized studyAlejandra Esteves-Jaramillo, Timothy Koehler, Robert Jeanfreau, et al.
Infectious Diseases and Therapy|September 27, 2023
Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and OlderDavid Neveu, Tamala Mallett Moore, Betzana Zambrano, et al.
Vaccine|November 17, 2012
Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adultsThierry Kamtchoua, Monica Bologa, Robert Hopfer, et al.
Vaccine|November 8, 2012
Safety and immunogenicity of a pneumococcal histidine triad protein D vaccine candidate in adultsMichael Seiberling, Monica Bologa, Roger Brookes, et al.
Human Vaccines & Immunotherapeutics|June 4, 2021
Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center studyFranco M Piazza, Miia Virta, Marita Paassilta, et al.
Vaccine|February 11, 2022
Safety and immunogenicity of an investigational quadrivalent meningococcal tetanus toxoid conjugate vaccine (MenACYW-TT) co-administered with routine pediatric vaccines in infants and toddlers: A Phase II studyMatthew J Cornish, James A Hedrick, Alvin A Gabrielsen, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|June 22, 2005
Tintin in CMAJDavid Neveu
Vaccine|June 23, 2020
Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: A Phase III randomized studyMandeep S Dhingra, James Peterson, James Hedrick, et al.
Infectious Diseases and Therapy|January 13, 2021
Post-Marketing Surveillance Observational Study of Quadrivalent Meningococcal Diphtheria Toxoid Conjugate Vaccine (MenACWY-DT, MCV4/Menactra<sup>®</sup>) in the Republic of Korea, 2014-2019Hee Soo Kim, Solene Engel, David Neveu, et al.
Vaccine|February 25, 2025
Corrigendum to "Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: A Phase III randomized study" [Vaccine (38) (2020) 5194-5201]Mandeep S Dhingra, James Peterson, James Hedrick, et al.
Vaccine|May 11, 2020
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in ≥56-year-olds: A Phase III randomized studyAlejandra Esteves-Jaramillo, Timothy Koehler, Robert Jeanfreau, et al.
Infectious Diseases and Therapy|September 27, 2023
Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and OlderDavid Neveu, Tamala Mallett Moore, Betzana Zambrano, et al.
Vaccine|November 17, 2012
Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adultsThierry Kamtchoua, Monica Bologa, Robert Hopfer, et al.
Vaccine|November 8, 2012
Safety and immunogenicity of a pneumococcal histidine triad protein D vaccine candidate in adultsMichael Seiberling, Monica Bologa, Roger Brookes, et al.
Human Vaccines & Immunotherapeutics|June 4, 2021
Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center studyFranco M Piazza, Miia Virta, Marita Paassilta, et al.
Vaccine|February 11, 2022
Safety and immunogenicity of an investigational quadrivalent meningococcal tetanus toxoid conjugate vaccine (MenACYW-TT) co-administered with routine pediatric vaccines in infants and toddlers: A Phase II studyMatthew J Cornish, James A Hedrick, Alvin A Gabrielsen, et al.
Pageof 1